Rocket Lab Corporation reports Q1 2026 results tomorrow evening with short sellers at their most active in months — and a fresh cohort of bullish analysts raising targets into the print.
Short interest has nearly doubled since mid-March, climbing from roughly 3.4% of free float to 6.3% today. The steepest leg came in the final week of April, when bearish positions jumped by almost 30% in a single week to reach levels not seen in the trailing 50-day window. That acceleration is the week's defining data point. It coincides with the stock's 16% one-month price surge, suggesting the new shorts are leaning against valuation rather than fading a deteriorating story. The lending market does not yet validate the bear conviction: availability remains very loose at around 630% — more than six shares available to borrow for every one already lent out — and the cost to borrow has actually fallen sharply, down 23% over the past week to just 0.33% annualised. Options positioning is similarly subdued: the put/call ratio of 0.75 is almost exactly in line with its 20-day average, with a z-score close to zero, offering no directional signal ahead of the release.
The Street has turned noticeably more constructive over the past month. Stifel raised its target to $105 earlier in April while reiterating Buy, and Roth Capital followed by lifting its target to $100. Citizens upgraded the stock outright to Market Outperform in early April. That three-firm cluster of positive actions in a single month stands in clear contrast to the only explicit sceptic on the recent tape: Wells Fargo initiated coverage at Equal-Weight with a $60 target on April 1st — about 24% below the current price. Goldman Sachs holds a Neutral rating with a $69 target, keeping it as the most prominent bearish voice on valuation. The consensus mean target is around $90, roughly 14% above the current $78.76 close, implying the average analyst sees modest upside but is not chasing the stock here. With the stock trading at a price-to-book of 29x and an EV/EBITDA multiple that is effectively non-meaningful given current earnings, valuation is the clear sticking point for bears — and bulls are arguing that forward growth justifies the premium.
Factor scores reinforce that growth-versus-valuation tension. The EPS 12-month forward year-on-year increase ranks in the 97th percentile of the universe, meaning the market is pricing in exceptional growth. Yet EPS momentum scores for both the 30-day and 90-day windows are in the bottom 5%, signalling that near-term estimate revisions have run in the wrong direction. The company's EPS surprise rank is a strong 90th percentile, so it has a consistent record of beating consensus — but the bar for tomorrow's print is clearly rising as the stock approaches $80. The short score of 43.5 has been grinding higher through April, up from around 38 at the start of the month, reflecting the accumulation in bearish positioning without yet reaching the extreme ranges that would signal a crowded short.
On institutional flows, Vanguard added roughly 6.1 million shares in the quarter to March 31, lifting its stake to 8.2% of shares — the largest holder on the register. BlackRock added 1.7 million shares to 5.7%, and JP Morgan Asset Management nearly doubled its position by adding 3.5 million shares in the same period. The institutional tide is clearly flowing in. Insider activity ran the other way: the COO and General Counsel both sold meaningful positions in early March, with the COO trimming more than $2.6 million in aggregate across multiple tranches. Those sales came at prices in the $70-$75 range, so the stock is now trading above those exit levels — a modest mark against the insider thesis, though scheduled sales plans often explain these moves.
The last two earnings prints both produced negative next-day moves: roughly -2.3% after the November 2025 release and -1.6% after February 2026. Neither reaction was severe, but neither showed the kind of post-earnings jump bulls might need to shake out the new short cohort. With short interest at a six-week high, availability loose, and the stock up 16% in a month, tomorrow's Q1 print resolves a clear stand-off between well-positioned institutional buyers and a freshly rebuilt short book leaning on valuation. The print on May 7th is therefore less about whether Rocket Lab is growing and more about whether the growth rate justifies the multiple that new buyers have been willing to pay.
See the live data behind this article on ORTEX.
Open RKLB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
